0.00Open7.50Pre Close0 Volume1 Open Interest100.00Strike Price0.00Turnover0.00%IV65.09%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier-3DDays to Expiry7.50Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma35.33Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet